Liraglutide is categorized as GLP-1 receptor agonist; its regulatory category in this atlas is FDA-approved peptide drug or regulated peptide/hormone medication.
Fda LabelPEPTIDE DOSSIER
Liraglutide
Liraglutide is classified as GLP-1 receptor agonist. This profile separates what is known from source-linked evidence, what remains uncertain, safety considerations, and the US regulatory context.
SaxendaVictoza
Executive Summary
What is it?
Liraglutide is a profile in the atlas because people search for it as a peptide, peptide medicine, peptide-like hormone, supplement ingredient, cosmetic peptide, or nearby comparison item. The key question is not just what it is called, but whether a specific product has reliable evidence, clear safety information, and a verified regulatory pathway.
What is it used or studied for?
Liraglutide is commonly searched in connection with Chronic weight management, Type 2 diabetes product exists under separate label. Some uses may be approved for specific products, while others may only be studied, speculative, cosmetic, supplement-related, or unsupported.
How it interacts with the body
In simple terms, Liraglutide is discussed through GLP-1 receptor agonism. That means the profile focuses on the body signal, receptor, or pathway it is believed or known to affect, while separating proven labeled uses from research-only claims.
What we know
- - Liraglutide is categorized as GLP-1 receptor agonist.
- - Liraglutide currently has evidence grade A in this atlas.
- - Regulatory category: FDA-approved peptide drug or regulated peptide/hormone medication.
What remains uncertain
- - Product-specific legality, quality, and labeling can vary by jurisdiction and supplier.
- - Long-term safety and real-world adverse-event patterns may be incomplete outside approved product contexts.
- - Claims not tied to FDA labeling or human trials should be treated cautiously.
Non-technical takeaway
Liraglutide should be read through three filters: what the evidence says, what the regulatory status actually means, and what safety uncertainties remain.
People usually search Liraglutide to understand potential uses, how it works in the body, whether it is approved, and what safety concerns or evidence gaps matter.
Key safety considerations
Safety context for Liraglutide should be interpreted through product-specific labels or the limits of available research. Non-approved products should not be treated as safe for human use.
Chemical and Scientific Profile
- Peptide type
- GLP-1 receptor agonist
- Sequence
- Unknown
- Formula
- Unknown
- Molecular weight
- Unknown
- CAS number
- Unknown
- PubChem CID
- 16134956
- Targets
- GLP-1 receptor
- Routes studied
- subcutaneous
Molecular visualization placeholder
Mechanism of Action
Explain like I’m new
Liraglutide is discussed through the pathway: GLP-1 receptor agonism. The plain-language interpretation should stay anchored to verified evidence and labeled uses.
Advanced scientific view
Advanced view: GLP-1 receptor agonism. Receptor/pathway details require claim-level citations before being treated as clinically meaningful.
GLP-1 receptor agonism
Benefits and Claims
Supported
Liraglutide should be interpreted through source-linked evidence, not marketing claims or protocol claims.
Human RctUnsupported / Safety Claim
Liraglutide has product-specific label warnings and should only be used under licensed clinician supervision according to the prescribing label.
Fda LabelEvidence Dashboard
A
Evidence grade
FDA label and human clinical evidence for labeled uses
Human data
not the primary evidence basis for labeled uses
Animal data
high for labeled uses
Citation quality
large human randomized controlled trial
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Population
- See linked source record for enrolled population.
- Intervention
- Liraglutide
- Comparator
- See linked source record.
- Outcomes
- See linked source record for primary and secondary outcomes.
- Limitations
- This study card is a seed-level summary and should be replaced by full PICO extraction during editorial review.
- Funding/conflict
- Funding and conflict notes require editorial extraction from the full source.
Dosing and Administration Guardrails
Use only according to the approved prescribing information and a licensed clinician. This site does not provide dosing instructions.
This site does not provide personalized protocols, DIY preparation, injection, reconstitution, or self-administration instructions.
Safety Section
Common side effects
- - nausea
- - vomiting
- - diarrhea
- - constipation
- - injection-site reaction
Serious warnings
- - thyroid C-cell tumor risk language
- - pancreatitis
- - gallbladder disease
- - kidney injury
Contraindications
- - personal or family history of medullary thyroid carcinoma
- - multiple endocrine neoplasia syndrome type 2
Interactions
- - insulin or insulin secretagogues may increase hypoglycemia risk
Regulatory and Sport Status
Comparisons
Compare evidence, regulatory status, route, and safety context before treating two compounds as similar.
FAQs
Is Liraglutide FDA-approved?
Liraglutide appears in an FDA-regulated product context for specific labeled uses. Approval applies to the specific product and indication, not every market product using the same ingredient name.
What is the main evidence caveat for Liraglutide?
Liraglutide is categorized as FDA-approved peptide drug or regulated peptide/hormone medication. Evidence strength depends on whether a claim comes from FDA labeling, human trials, animal studies, in vitro work, or unsupported marketing.
Does this page provide dosing instructions for Liraglutide?
No. For approved products, this site points users back to the prescribing label and a licensed clinician.